Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy
Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), slashing the price of…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025
Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong…
-
Genentech wins FDA approval for second stroke treatment
Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label expansion…
-
Rare disease treatments skipping UK patients largely due to costs, survey shows
UK patients living with rare diseases are not being offered many of the life-changing medicines being developed, mainly due to…
-
Why pharma is still far from a treatment for galactosemia
Nearly three months after an experimental treatment for classic galactosemia was rejected by the US Food and Drug Administration (FDA),…
-
UK M&A activity down in January amid uncertain US opportunities
The number of deals in the UK healthcare mergers & acquisition (M&A) sector in January 2025 was down from the…
-
Idorsia’s Tryvio deal collapses, forcing company to find cash urgently
A deal that would have seen Idorsia sell global rights to hypertension drug Tryvio (aprocitentan) has fallen through, leaving the…
-
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract
Johnson & Johnson (J&J) has sued Samsung Bioepis over a ‘concealed plan’ to supply an unnamed health conglomerate with a…
-
Semaglutide shortage ends as FDA sets deadline for compounders
Compounders are on alert after the US Food and Drug Administration (FDA) declared the shortage of semaglutide –the active ingredient…
-
Pfizer shelves haemophilia gene therapy Beqvez amid low demand
Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A…